Ursolic acid and empagliflozin combo better for treating diabetic nephropathy, study finds

China: A recent study in the journal Biomedicine & Pharmacotherapy has shown that a combination of ursolic acid (UA) and empagliflozin (EM) is more effective than the respective monotherapy for the treatment of diabetic nephropathy (DN). They do so by reducing oxidative stress, inflammation, and renal fibrosis, and by canceling each other's adverse effects. 

Both the drugs cancel each other's adverse effects; Ursolic acid can reduce the side effects of empagliflozin LDL-L increase and urinary tract infection. Further, the combo treatment was shown to overcome the disadvantages of the slow hypoglycaemic effect of UA.

Previous studies have shown UA and empagliflozin to have therapeutic effects in the DN treatment, but both drugs have some disadvantages. The study by Xiaohan Wu, Zhengzhou University, Zhengzhou City, Henan Province, China, and colleagues, therefore, explores the effect of combining these drugs compared to that of either monotherapy. 

For carrying out the study, Dr. Xiaohan, and the team established a diabetic rat model by feeding a high-fat diet (HFD) with high-sugar content and administering a low dose of streptozotocin (STZ) via intraperitoneal injection. UA (50 mg/kg/day, po), EM (10 mg/kg/day, po) or both were administered for 8 weeks. DN development was determined by observing increases in serum creatinine, urine protein, urea nitrogen, and uric acid and abnormal changes in kidney morphology.